These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 17430671)

  • 1. [A case report of paclitaxel combined with carboplatin for poorly differentiated prostate cancer with renal failure].
    Chen JW; Meng QG; Tang Y; Xie D; Wang ZR
    Ai Zheng; 2007 Apr; 26(4):445-6. PubMed ID: 17430671
    [No Abstract]   [Full Text] [Related]  

  • 2. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
    Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
    Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment of primary peritoneal carcinoma with paclitaxel and carboplatin combination chemotherapy].
    Tohya T; Ujioka T; Yamaguchi M
    Gan To Kagaku Ryoho; 2008 Jan; 35(1):153-5. PubMed ID: 18195548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    von der Maase H
    Eur Urol; 2007 Oct; 52(4):1122. PubMed ID: 17433856
    [No Abstract]   [Full Text] [Related]  

  • 6. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer.
    Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ
    J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II.
    Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A
    J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.
    Mazgani M; Le N; Hoskins PJ;
    Gynecol Oncol; 2008 Dec; 111(3):474-7. PubMed ID: 18929402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.
    Chiappori AA; Haura E; Rodriguez FA; Boulware D; Kapoor R; Neuger AM; Lush R; Padilla B; Burton M; Williams C; Simon G; Antonia S; Sullivan DM; Bepler G
    Clin Cancer Res; 2008 Mar; 14(5):1464-9. PubMed ID: 18316570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metastatic myoepithelial carcinoma of the vulva treated with carboplatin and paclitaxel.
    Noronha V; Cooper DL; Higgins SA; Murren JR; Kluger HM
    Lancet Oncol; 2006 Mar; 7(3):270-1. PubMed ID: 16510337
    [No Abstract]   [Full Text] [Related]  

  • 16. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Cetnar JP; Malkowicz SB; Palmer SC; Wein AJ; Vaughn DJ
    Urology; 2008 May; 71(5):942-6. PubMed ID: 18279928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer.
    Ramalingam S; Perry MC; La Rocca RV; Rinaldi D; Gable PS; Tester WJ; Belani CP
    Cancer; 2008 Aug; 113(3):542-6. PubMed ID: 18512224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
    Thall PF; Logothetis C; Pagliaro LC; Wen S; Brown MA; Williams D; Millikan RE
    J Natl Cancer Inst; 2007 Nov; 99(21):1613-22. PubMed ID: 17971530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly paclitaxel and high-dose 5-fluorouracil plus leucovorin in hormone-refractory prostate cancer: in vitro combined effects and a phase II trial.
    Lin CC; Hsu CH; Hour TC; Cheng AL; Huang CY; Huang KH; Chen J; Pu YS
    Urol Oncol; 2007; 25(3):207-13. PubMed ID: 17483017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.